Retinalamin

Injectable complex of water-soluble polypeptide fractions extracted from cattle retina, used in Russian ophthalmology for glaucoma and retinal disease; its evidence base is largely Russian-language clinical literature, with no FDA approval or registered Western trials.

Also referenced as: Retinalamine, retinal polypeptide complex, cattle retina polypeptides

Also appears in: Other

What is Retinalamin?

Retinalamin is not a single defined-sequence peptide: it is a complex of water-soluble, low-molecular-weight polypeptide fractions extracted from the retinas of cattle, developed within the Russian “peptide bioregulator” (cytomedine) research tradition associated with the St. Petersburg Institute of Bioregulation and Gerontology and manufactured by Geropharm. In Russia and several CIS countries it is a registered prescription drug, given by intramuscular or parabulbar injection in ophthalmology for conditions such as compensated open-angle glaucoma, diabetic retinopathy, and central retinal dystrophies. It appears on the research-peptide market as a gray-market import of the Russian pharmaceutical product, since it has no marketing authorization in the United States or Europe.

How it works

Because Retinalamin is an undefined tissue extract, its mechanism is characterized at the level of the whole preparation rather than a single molecule. Proposed mechanisms from the primary literature include:

• Glutamate receptor interaction. Competitive radioligand binding assays showed significant interaction of the cattle-retina polypeptide complex with AMPA, NMDA, and mGluR1 glutamate receptor subtypes — receptor systems implicated in retinal ganglion cell loss — and mouse biodistribution studies tracked accumulation in eye and brain tissue after intravenous, intramuscular, and parabulbar administration (Verlov et al., Vestnik Oftalmologii, 2021;137(5):94-101).
• Tissue-specific stimulation of retinal cell proliferation. In cell culture, Retinalamin — tested alongside the synthetic tetrapeptide Epitalon (Ala-Glu-Asp-Gly) — stimulated proliferation of retinal and pigmented epithelial cells tissue-specifically at certain concentrations (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003;135(6):597-599).
• Inductive activity on neural differentiation. In a classical embryology model, Retinalamin drove concentration-dependent neuronal differentiation of Xenopus laevis early gastrula ectoderm toward brain, retina, and pigment epithelium lineages (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2002;134(5):482-484).

Research status

Retinalamin is a registered drug in Russia, but essentially all of its clinical evidence comes from Russian-language journals, and the published studies are randomized but not described as blinded or placebo-controlled in their indexed reports.

The two largest clinical studies are both in Vestnik Oftalmologii. Egorov et al. (2019;135(3):20-30) randomized 180 patients (355 eyes) with open-angle glaucoma and normalized intraocular pressure to intramuscular Retinalamin courses or control; over 12 months the treated group’s visual field mean deviation improved while the control group’s declined, with stabilization of ganglion cell complex thickness and pattern-ERG parameters. Strakhov et al. (2020;136(5):58-66) followed 147 patients (249 eyes) with stage I-II glaucoma for 24 months with treatment courses every 6 months; retinal nerve fiber layer thickness held stable in the treated group while declining in controls, but the results were mixed — pattern standard deviation worsened significantly in both groups, and the groups’ perimetry indices converged by study end. Smaller Russian reports cover diabetic retinopathy, retinal dystrophies, and tuberculous chorioretinitis.

The preclinical record is not uniformly positive. An independent study at a Russian military-medicine institute found no significant functional or morphological neuroprotective effect of Retinalamin in a randomized, saline-controlled rabbit model of photochemical retinal damage — electroretinography, histology, and TUNEL apoptosis counts all showed no difference from control (Suetov et al., Vestnik Oftalmologii, 2021;137(5):57-67).

There are no studies of Retinalamin registered on ClinicalTrials.gov, no FDA review or DailyMed label, and no published Western randomized controlled trials.

Common dosage forms

The pharmaceutical product is a lyophilized powder for injection: 5 mg of the polypeptide complex per vial with glycine as a stabilizer, typically sold in 10-vial cartons and reconstituted for intramuscular or parabulbar administration. Research-market and international-pharmacy listings generally mirror this format — 5 mg lyophilized vials, often the Geropharm-branded Russian pharmacy product itself. There is no oral or topical form of the drug; orally dosed “retina peptide” capsules sold in the supplement market are different products.

Key considerations

• Regulatory status. Retinalamin is a prescription drug in Russia and some CIS countries only. It is not FDA-approved, has never been reviewed by the FDA or EMA, and is not legally marketed as a drug in the United States; availability outside its home markets is gray-market importation.
• Evidence gaps. The clinical literature is almost entirely Russian-language, and the key randomized studies do not report blinding or placebo control. No trials are registered on ClinicalTrials.gov, so the usual mechanisms for verifying prespecified endpoints do not apply.
• Mixed and negative results exist. The 24-month Strakhov study showed visual-field deterioration in both treated and control groups on some indices, and a 2021 controlled rabbit study found no neuroprotective effect at all — the evidence should not be read as uniformly positive.
• Undefined composition. As an animal-tissue extract with no published sequence, Retinalamin cannot be identity- or purity-verified the way synthetic peptides can; composition is defined by the manufacturing process, and batch-to-batch variability cannot be independently assessed. Bovine tissue origin also carries the sourcing and immunogenicity considerations common to animal-derived injectable biologics.
• Naming confusions. Retinalamin is unrelated to the vitamin-A compounds retinal, retinol, and tretinoin (Retin-A), and is distinct from oral “retina bioregulator” dietary supplements (such as Visoluten) that come from the same St. Petersburg research lineage but are different, non-drug products.